Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Alexandra Schifferli"'
Autor:
Alexandra Schifferli, Guillaume Moulis, Bertrand Godeau, Thierry Leblanc, Nathalie Aladjidi, Marc Michel, Guy Leverger, Mohsen Elalfy, John Grainger, Meera Chitlur, Andrea Heiri, Susanne Holzhauer, Gautier le Gavrian, Paul Imbach, Thomas Kühne
Publikováno v:
Haematologica, Vol 108, Iss 10 (2023)
Current immune thrombocytopenia (ITP) guidelines target children and adults, leading to oversimplification. Adolescents and young adults (AYAS) comprise a separate group with distinct health and psychosocial issues. This study aimed to describe the c
Externí odkaz:
https://doaj.org/article/77b6aa237b1c4627bdede6618a6b783a
Autor:
Alexandra Schifferli, Franco Cavalli, Bertrand Godeau, Howard A. Liebman, Mike Recher, Paul Imbach, Thomas Kühne
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
The pathogenesis of immune thrombocytopenia (ITP) is increasingly being elucidated, and its etiology is becoming more frequently identified, leading to a diagnostic shift from primary to secondary ITP. The overlap between autoimmunity, immunodeficien
Externí odkaz:
https://doaj.org/article/da64c461a33f4284bc63867435d6cd67
Autor:
Charlotte Adamczick, Alexa Dierig, Tatjana Welzel, Alexandra Schifferli, Johannes Blum, Nicole Ritz
Publikováno v:
BMC Infectious Diseases, Vol 18, Iss 1, Pp 1-5 (2018)
Abstract Background Leishmaniasis is endemic in many countries worldwide, with a prevalence of 12 million people infected, and an estimated annual incidence of 500 000 visceral leishmaniasis cases. In Europe visceral leishmaniasis is considered endem
Externí odkaz:
https://doaj.org/article/4ed4cf0e13b94f92994710ed6155711b
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Fc fusion proteins and Fc fusion peptides or peptibodies are chimeric molecules composed of an active pharmacological protein or peptide and the Fc fragment of an immunoglobulin. The primary aim of this drug construct is to prolong the half-life of t
Externí odkaz:
https://doaj.org/article/2dd22fd433fa45a3b47ed62f19baeac7
Long-Term Outcome of Adolescents and Young Adults with Chronic Primary Immune Thrombocytopenia (ITP)
Autor:
Alexandra Schifferli, Gautier Le Gavrian, Nathalie Aladjidi, Guillaume Moulis, Bertrand Godeau, Thierry Leblanc, Marc Michel, Guy Leverger, Helder Fernandes, Thomas Kuehne
Publikováno v:
Blood. 140:5551-5552
Autor:
Susanne Holzhauer, Diane J. Nugent, Thomas Kühne, Paul Imbach, Markus G. Seidel, Marc Michel, Andrea Heiri, Alexandra Schifferli
Publikováno v:
Blood Adv
Primary immune thrombocytopenia (ITP) in children is a diagnosis of exclusion, but cases of secondary ITP and nonimmune thrombocytopenia (non-IT) are generally difficult to recognize in a timely fashion. We describe a pediatric population with a revi
Publikováno v:
Orthopädie und Unfallchirurgie ISBN: 9783642546730
Orthopädie und Unfallchirurgie
Orthopädie und Unfallchirurgie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65059762bab89bf4be3fe92e633759c7
https://doi.org/10.1007/978-3-642-54673-0_239-1
https://doi.org/10.1007/978-3-642-54673-0_239-1
Publikováno v:
Pädiatrie up2date. 13:139-150
Autor:
Thomas Kühne, Runhui Wu, Paul Imbach, John D. Grainger, Hannah Tamary, Cecilia Riccheri, Francesco Rodeghiero, Hugo Donato, Tatjana Uglova, Mohsen Saleh Elalfy, Meera Chitlur, Alexandra Schifferli, Elena Graciela, Marco Ruggeri, Susanne Holzhauer, Andreas Holbro, Michael Coslovsky
Publikováno v:
American Journal of Hematology. 93:751-759
Comparative clinical studies of children and adults with immune thrombocytopenia (ITP) are poorly covered in the literature. However, the accepted classification of ITP-childhood ITP and adult ITP-results in considerable differences in treatment prot
Autor:
Thomas Kuehne, Heike Faeth, Andreas Holbro, Axel Rüfer, Renata Rosa Pereira, Nathan Cantoni, Geneviève Favre, Anna Wieland, Falk Nimmerjahn, Alexandra Schifferli, Alicia Rovó, Jan Dirks
Publikováno v:
Blood. 138:3149-3149
Introduction : To date most treatment strategies of primary immune thrombocytopenia (ITP) are symptomatic, preventing premature platelet destruction and increasing their production. New strategies should focus on targeting the immune dysregulation, r